Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Relapsed or Refractory DLBCL | US/EU | 2019

Login to access report north_east
Contact sales account_box

MARKET OUTLOOK

Relapsed/refractory diffuse large B-cell lymphoma (R/RDLBCL) represents an area of high unmet need in non-Hodgkin’s lymphoma (NHL) due to the poor outcomes with current salvage treatment. Rituximab-based chemoimmunotherapy regimens (e.g., R-DHAP, R-ICE, R-ESHAP) are the conventional standard of care for R/RDLBCL followed by conditioning and autologous or allogeneic stem cell transplantation (SCT) in eligible patients. The anti-CD19 CAR T-cell therapies Yescarta (Gilead/Kite) and Kymriah (Novartis) have expanded treatment options for patients with DLBCL, although their current use is restricted to third and subsequent lines of therapy. Despite the evolving market landscape, significant unmet need remains in the treatment of R/RDLBCL due to the limited availability of effective treatment options.

QUESTIONS ANSWERED

  • What are the most important factors that drive hematologist-oncologists’ prescribing decisions for R/R DLBCL?
  • How do current therapies perform on key clinical attributes for R/R DLBCL?
  • What are the major unmet needs and the most lucrative opportunities in R/R DLBCL?
  • When considering new treatment options in this setting, what trade-offs are acceptable to surveyed hematologist-oncologists between key clinical attributes and cost of therapy?

Markets covered: United States, France, Germany, United Kingdom.

Primary research: Survey of 60 U.S. hematologist-oncologists and 30 European hematologist-oncologists.

Key companies: Gilead, Kite Pharma, Novartis, Roche / Genentech.

Key drugs: Rituximab, Yescarta, Kymriah.

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
north_east
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
north_east
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
north_east
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
north_east
Report
Obesity / Overweight – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity / Overweight (US)
As the prevalence of obesity rises, the demand for safe and effective treatments increases. Therapies mimicking GLP-1 and GIP peptides—hormones that regulate appetite and energy metabolism—have…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east